Mueller H S
Department of Medicine, Montefiore Medical Center, Bronx, NY 10467.
Cardiology. 1994;84(3):168-74. doi: 10.1159/000176395.
IACP has played an important role in the evolution of the therapy of cardiogenic shock. Although IACP has not developed to an independent treatment modality, it is an essential adjunct to facilitate early catheterization and reperfusion strategies. With this combined approach, hospital and long-term survival rates have reached encouraging results. In acute myocardial infarction, IACP may evolve into an intriguing adjunct to thrombolysis and/or PTCA. Preliminary data suggest that IACP might decrease the rate of reocclusion and reinfarction after thrombolysis and/or PTCA and, thus, interrupt the vicious cycle of infarct extension, development of left-ventricular failure and cardiogenic shock. Further research is in progress.
主动脉内球囊反搏术(IACP)在心源性休克治疗的发展过程中发挥了重要作用。尽管主动脉内球囊反搏术尚未发展成为一种独立的治疗方式,但它是促进早期导管插入术和再灌注策略的重要辅助手段。通过这种联合方法,医院存活率和长期存活率都取得了令人鼓舞的结果。在急性心肌梗死中,主动脉内球囊反搏术可能会演变成溶栓和/或经皮冠状动脉腔内血管成形术(PTCA)的一种有趣的辅助手段。初步数据表明,主动脉内球囊反搏术可能会降低溶栓和/或PTCA后的再闭塞率和再梗死率,从而中断梗死扩展、左心室衰竭发展和心源性休克的恶性循环。进一步的研究正在进行中。